Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Advanced Gastric Carcinoma Pipeline Insight" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Gastric Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Gastric Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

* In October 2024:- Jazz Pharmaceuticals- A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA). The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
* In October 2024: -AstraZeneca- An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
* In October 2024:- Shanghai Miracogen Inc.- The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
* In October 2024:- Servier Bio-Innovation LLC- This Phase 1b/2 study will be conducted in two parts; a safety lead-in part (Phase 1b) to identify the RP2D of S095029 in combination with pembrolizumab and an expansion part (Phase 2) to evaluate anti-tumor activity and safety in participants with locally advanced unresectable or metastatic MSI-H/dMMR gastric /GEJ adenocarcinomas.
* In October 2024;- Amgen- A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression. The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.
* In October 2024:- Hoffmann-La Roche- This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.
* In October 2024:- Viracta Therapeutics, Inc.- This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
* In October 2024:- Suzhou Transcenta Therapeutics Co., Ltd.- This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.
* DelveInsight's Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
* The leading Advanced Gastric Carcinoma Companies such as Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc ., and others.
* Promising Advanced Gastric Carcinoma Therapies such as MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.

Stay informed about the cutting-edge advancements in Advanced Gastric Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Gastric Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Gastric Carcinoma Emerging Drugs Profile

* Camrelizumab: Jiangsu Hengrui Medicine

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

* Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Learn more about Advanced Gastric Carcinoma Drugs Opportunities in our groundbreaking Advanced Gastric Carcinoma Research and development projects @ Advanced Gastric Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type

Advanced Gastric Carcinoma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Discover the latest advancements in Advanced Gastric Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Gastric Carcinoma Pipeline Report

* Coverage- Global
* Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
* Advanced Gastric Carcinoma Therapies- MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.
* Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Gastric Carcinoma Pipeline on our website @ Advanced Gastric Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Gastric Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Gastric Carcinoma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Camrelizumab: Jiangsu Hengrui Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Pamiparib: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Venadaparib: Idience
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Gastric Carcinoma Key Companies
* Advanced Gastric Carcinoma Key Products
* Advanced Gastric Carcinoma- Unmet Needs
* Advanced Gastric Carcinoma- Market Drivers and Barriers
* Advanced Gastric Carcinoma- Future Perspectives and Conclusion
* Advanced Gastric Carcinoma Analyst Views
* Advanced Gastric Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-gastric-carcinoma-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.